We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$150M 5.44%
1,942,317
-121,382
-6% -$9.17M
AMGN icon
2
Amgen
AMGN
$209B
$141M 5.1%
677,855
-22,733
-3% -$4.48M
BIIB icon
3
Biogen
BIIB
$30.7B
$138M 5.02%
391,402
-12,553
-3% -$4.32M
JNJ icon
4
Johnson & Johnson
JNJ
$617B
$138M 5%
996,968
+103,886
+12% +$13.8M
CELG
5
DELISTED
Celgene Corp
CELG
$117M 4.26%
1,312,350
+60,880
+5% +$5.38M
UNH icon
6
UnitedHealth
UNH
$383B
$91.6M 3.32%
344,486
-80,831
-19% -$21M
ILMN icon
7
Illumina
ILMN
$31B
$89.1M 3.23%
249,513
-42,945
-15% -$13.8M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$122B
$78.7M 2.85%
408,235
-173,287
-30% -$30.9M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$60.9M 2.21%
438,416
– –
VTRS icon
10
Viatris
VTRS
$20.7B
$60.6M 2.2%
1,657,017
– –
PFE icon
11
Pfizer
PFE
$142B
$59.7M 2.16%
1,427,214
-1,059,896
-43% -$40.8M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$77.4B
$59.1M 2.14%
146,237
– –
AGN
13
DELISTED
Allergan plc
AGN
$47.4M 1.72%
248,836
– –
ABBV icon
14
AbbVie
ABBV
$455B
$46.5M 1.69%
492,078
-21,580
-4% -$2.05M
MRK icon
15
Merck
MRK
$321B
$45.8M 1.66%
676,178
-669,477
-50% -$42.7M
INCY icon
16
Incyte
INCY
$24.9B
$44.6M 1.62%
645,442
– –
TMO icon
17
Thermo Fisher Scientific
TMO
$214B
$44M 1.6%
180,395
+27,700
+18% +$6.37M
ELV icon
18
Elevance Health
ELV
$81.6B
$38.7M 1.4%
141,147
+30,514
+28% +$7.92M
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.64B
$36M 1.31%
223,182
-11,307
-5% -$1.55M
MDT icon
20
Medtronic
MDT
$110B
$33.4M 1.21%
339,439
-84,254
-20% -$7.79M
CVS icon
21
CVS Health
CVS
$134B
$31.6M 1.15%
401,101
+34,580
+9% +$2.47M
ABT icon
22
Abbott
ABT
$183B
$28.7M 1.04%
391,719
-235,300
-38% -$15.4M
SYK icon
23
Stryker
SYK
$133B
$28.5M 1.03%
160,432
+23,801
+17% +$4.06M
AZN icon
24
AstraZeneca
AZN
$266B
$28.4M 1.03%
359,312
-30,132
-8% -$2.28M
NVS icon
25
Novartis
NVS
$301B
$27.8M 1.01%
360,122
+29,987
+9% +$2.22M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.